App-Quantinova.ai

Defining distinct fibroblast populations in systemic sclerosis skin using functional characterization and single-cell RNA sequencing

Kristina E Clark - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Scleroderma

Collagenase

Clinical trajectories and predictors of hand function deterioration in systemic sclerosis

Enrico De Lorenzis - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Scleroderma

N/A

Pilot study to determine whether skin blood flow, oxygenation and skin colour are related in patients with systemic sclerosis

Graham Dinsdale - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Scleroderma

N/A

Systemic Sclerosis Dermal Fibroblast-derived Exosomes trigger a Type I Interferon Response in Keratinocytes, through Tank Binding Kinase 1

Jessica A Bryon - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Scleroderma

Interferon

Biosamples from VEDOSS patients show classic pathological signs of Scleroderma:Opportunity for a biological diagnosis of disease

Rebecca L Ross - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Scleroderma

IFN-lambda

An emerging role of interferon targeted therapy in mucocutaneous SLE: a prospective real-world evaluation of anifrolumab for refractory cutaneous lupus

Lucy Marie Carter - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

MDX1333

The incidence of cancer in SLE patients receiving biologic therapy: Results from the British Isles Lupus Assessment Group Biologics Registry (BILAG-BR)

Mia Rodziewicz - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Belimumab

Overcoming rituximab resistance in autoimmune disease: back to basics

Kavina Shah - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

Rituximab

Treatment effects of ixekizumab and adalimumab at the individual digit level with nail and distal interphalangeal joint involvement in patients with psoriatic arthritis

Dennis McGonagle - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Psoriatic arthritis

Adalimumab

Identifying predictors of axial spondyloarthritis flare onset using daily patient-reported data collected via a smartphone app

Alexandra Kypta-Vivanco - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Axial spondyloarthritis

N/A

Bimekizumab in bDMARD-naïve patients with active psoriatic arthritis: improvements in PsARC over 24 weeks in the Phase 3 BE OPTIMAL trial

Iain McInnes - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Psoriatic arthritis

bimekizumab

Evaluating the use of patient reported outcome measures to assess intra-pandemic psoriatic arthritis disease activity and comparing them with pre-pandemic clinical assessments

Kaiyang Song - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Psoriatic arthritis

N/A

Psoriatic arthritis patients in the UK have a lower quality of life than patients in mainland Europe - an analysis from the ASSIST study

Conor Coyle - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Psoriatic arthritis

N/A

Creating a social movement for change to transform care and drive down diagnostic delay in axial SpA

Joe Eddison - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Axial spondyloarthritis

N/A

Minimal important difference, minimal detectable change and disease activity thresholds for two novel composite instruments, three visual analogue scale/VAS and four visual analogue scale/VAS, in patients with psoriatic arthritis: pooled analysis of three phase III studies

William Tillett - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Psoriatic arthritis

Grace

A UK survey evaluation of first contact practitioner and physiotherapist confidence, recognition and referral of suspected axial spondyloarthritis

Eliza Steen - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Axial spondyloarthritis

N/A

Current prescribing practices in psoriatic arthritis - comparison between the UK and Europe

Lily Watson - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Psoriatic arthritis

N/A

Shared decision-making in psoriatic arthritis consultations

Lily L Watson - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Psoriatic arthritis

N/A

Minimal disease activity response patterns in bio-naïve patients with psoriatic arthritis treated with guselkumab: a machine learning analysis

ALEN ZABOTTI - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Psoriatic arthritis

guselkumab (IV)

Assessing and improving mental health in axial spondyloarthritis through digital solutions

Antoni Chan - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Axial spondyloarthritis

N/A

Filters

45280 Abstracts